Apogee Therapeutics reported positive 16-week Phase 2 data from its APEX clinical trial of APG777, an anti-IL-13 antibody, in patients with moderate-to-severe atopic dermatitis. The trial met all primary and key secondary endpoints, showing a 71% reduction from baseline in Eczema Area and Severity Index (EASI) scores at week 16 compared to 34% for placebo. The drug demonstrated strong EASI-75 and EASI-90 responses, with rapid and significant pruritus relief observed by the first week. APG777 was well tolerated and offers less frequent dosing compared to existing treatments such as Sanofi's Dupixent (dupilumab). Apogee's market capitalization was approximately $2.9 billion at the time of the data release. The company is also exploring APG777's potential in asthma and eosinophilic esophagitis, as well as combination therapy with OX40L antibodies against Dupixent. Meanwhile, KalVista Pharmaceuticals received FDA approval for EKTERLY (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema (HAE), a rare and potentially life-threatening swelling disorder. Following the approval, KalVista's shares rose more than 17% in premarket trading. EKTERLY's approval marks a significant advancement in HAE treatment, providing patients with an oral alternative to existing therapies. The drug is being launched immediately after FDA clearance.